scholarly journals Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 759
Author(s):  
Nina Mørup ◽  
Ewa Rajpert-De Meyts ◽  
Anders Juul ◽  
Gedske Daugaard ◽  
Kristian Almstrup
Keyword(s):  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Primary Diagnosis ◽  
University Hospital ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Circulating Mirna ◽  
Serum Tumor Markers

New microRNA-based serum biomarkers (miRNA-367-3p, -371a-3p, -372-3p, and -373-3p) have shown great potential for the detection of testicular germ cell tumors (TGCTs), but few studies have investigated the clinical utility and performance of these tests in treatment monitoring. In this study, circulating miRNA levels were measured, together with serum tumor markers alpha-fetoprotein (AFP), β-subunit of human chorionic gonadotropin (β-HCG) and lactate dehydrogenase (LDH) in 406 consecutive blood samples obtained during the treatment and follow-up of 52 TGCT patients at the Copenhagen University Hospital. After testing three different methods of RNA isolation from peripheral blood and PCR quantification in a subset of samples (n = 15), the best performing setup of targeted isolation of miRNAs inside and outside exosomes was selected to analyze all samples. At primary diagnosis, the miRNAs significantly outperformed the serum tumor markers, with a sensitivity and specificity of 78% and 100% (based on 40 patients), respectively. The picture was not as clear when patient trajectories were investigated, with both positive and negative signals for miRNAs and serum tumor markers. To establish whether measuring miRNAs adds value beyond the primary diagnosis, large prospective clinical trials comparing miRNAs and classical tumor markers during the treatment and follow-up of TGCT patients are needed.

Serum tumor markers and testicular germ cell tumors: a primer for radiologists

2018 ◽  
Vol 44 (3) ◽  
pp. 1083-1090 ◽  
Author(s):  
Colin Marshall ◽  
Michael Enzerra ◽  
Amir Ata Rahnemai-Azar ◽  
Nikhil H. Ramaiya
Keyword(s):  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Serum Tumor Markers

Evaluation of Five Tumor Markers (AFP, CEA, hCG, hPL and SP1) in Monitoring Therapy and Follow-up of Patients with Testicular Germ Cell Tumors

Oncology ◽  
1983 ◽  
Vol 40 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Janusz J. Szymendera ◽  
Józef Zborzil ◽  
Ludwika Sikorowa ◽  
Jan Leńko ◽  
Janina A. Kamińska ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Monitoring Therapy

Importance of a new tumor market TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors

1997 ◽  
Vol 4 (4) ◽  
pp. 321-327 ◽  
Author(s):  
Mariël E. Gels ◽  
Jan Marrink ◽  
Petra Visser ◽  
Dirk Th. Sleijfer ◽  
Jos H. J. Droste ◽  
...  
Keyword(s):  
Germ Cell ◽  
Clinical Stage ◽  
Germ Cell Tumors ◽  
Stage I ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell

scholarly journals Testicular Germ Cell Tumors: Serological and Immunohistochemical Diagnosis

2021 ◽  
Vol 50 (1) ◽  
pp. 58
Author(s):  
Ivan Damjanov
Keyword(s):  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Testicular Tumor ◽  
Published Data ◽  
Routine Practice ◽  
Testicular Germ Cell Tumors ◽  
Testicular Tumors ◽  
Testicular Germ Cell ◽  
Immunohistochemical Markers

<p>This review deals with serologic and immunohistochemical tumor markers used in clinical laboratories for the diagnosis of testicular germ cell tumors. Time tested serologic markers such as alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are routinely used in the work-up of patients with testicular tumors. Professional organizations regulating the practice of medicine in most countries worldwide require that the laboratory values for these serologic reactants be included in the pathology reports on testicular tumors as part of the tumor staging process. Immunohistochemical markers of testicular germ have been identified and widely tested during the first two decades of the XXI century. We have selected the most useful immunohistochemical markers from a few of these markers and discussed them in this review.</p><p><strong>Conclusion</strong>. Published data show that testicular tumor markers are widely used in routine practice. The study of tumor markers has improved the pathologic and clinical diagnosis of testicular germ cell tumors and has thus contributed to their treatment.</p>

Clinical characteristics and treatment adherence among men with testicular germ cell tumors: Real-world data from a referral center in Mexico.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 393-393
Author(s):  
Carlos Eduardo Salazar-Mejía ◽  
Omar Zayas-Villanueva ◽  
Adriana González Gutiérrez ◽  
Rolando Jacob Martinez ◽  
ABRAHAM GUERRA CEPEDA ◽  
...  
Keyword(s):  
Germ Cell ◽  
Median Time ◽  
Treatment Adherence ◽  
Clinical Characteristics ◽  
Germ Cell Tumors ◽  
Collaborative Group ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Referral Center

393 Background: Notwithstanding excellent oncological outcomes reported by pivotal trials in patients with testicular germ cell tumors (TGCT), adherence to medical treatment and follow-up remains a major issue in developing countries. Studies that describe the clinical characteristics and treatment adherence of Mexican men with TGCT are lacking. Methods: We performed a retrospective analysis of all men with newly diagnosed TGCT treated at an oncology referral center in Northeast Mexico from 2014 to 2018. Results: In the analysis, 195 patients were included. Median age at diagnosis was 28 years; median time from diagnosis to first evaluation by an oncologist was 26 days. Distribution according to the laterality of the primary tumor was right, 56%; left, 43%; and bilateral, 1%. There were 14 oncological emergencies at presentation; the most frequent was choriocarcinoma syndrome, described in 5 patients. Thirty-five percent of cases were seminomatous germ cell tumors (SGCT) and 65% nonseminomatous germ cell tumors (NSGCT). The clinical stages at diagnosis were I, 36%; IS, 8%; II, 18%; and III, 38%. After risk stratification according to the International Germ Cell Cancer Collaborative Group (IGCCCG), 90% of SGCT had a good risk and 10% an intermediate risk. In NSGCT, the risk distribution was 65, 10, and 25% for good, intermediate, and poor-risk disease, respectively. After proposing treatment, the adherence rate was 81%. Of the total, 58% were lost to medical follow-up with a median time of adherence of 11.5 months. Conclusions: Despite coverage by the Mexican public health insurance system “Seguro Popular”, treatment adherence and medical follow-up abandonment is a problem among men with TGCT, which could negatively impact their prognosis. Measures must be implemented to optimize adherence in this group of patients.

The Role of Alkaline Phosphatase Isoenzymes as Tumor Markers for Testicular Germ Cell Tumors

1991 ◽  
Vol 146 (1) ◽  
pp. 57-60 ◽  
Author(s):  
K. Koshida ◽  
A. Nishino ◽  
H. Yamamoto ◽  
T. Uchibayashi ◽  
K. Naito ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Alkaline Phosphatase Isoenzymes

scholarly journals Cost Analysis of Noninvasive Blood-Based MicroRNA Testing Versus CT Scans for Follow-up in Patients With Testicular Germ-Cell Tumors

2019 ◽  
Vol 17 (4) ◽  
pp. e733-e744 ◽  
Author(s):  
Daniel Charytonowicz ◽  
Harry Aubrey ◽  
Chantelle Bell ◽  
Maeline Ferret ◽  
Keith Tsui ◽  
...  
Keyword(s):  
Cost Analysis ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Ct Scans ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell

scholarly journals The Past and Future of Biomarkers in Testicular Germ Cell Tumors

2020 ◽  
Vol 1 (1) ◽  
pp. 77-84
Author(s):  
Aditya Bagrodia ◽  
Siamak Daneshmand ◽  
Liang Cheng ◽  
James Amatruda ◽  
Matthew Murray ◽  
...  
Keyword(s):  
Germ Cell ◽  
Tumor Markers ◽  
Critical Role ◽  
Elevated Serum ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumor ◽  
Next Generation ◽  
Testicular Germ Cell ◽  
Circulating Micrornas ◽  
Serum Tumor Markers

Testicular germ cell tumor (GCT) is the most common malignancy in 18- to 40-year-old men. Unlike most other cancers, GCT is frequently curable even when metastatic. These tumors can be classified histologically into seminoma and non-seminoma, which determines treatment. Therefore, successful treatment requires accurate diagnosis, classification, and monitoring. Serum tumor markers, including lactate dehydrogenase, α-fetoprotein, and β-human chorionic gonadotropin, aid in the classification and staging of GCTs. These markers therefore play a critical role in the decision-making process when managing GCT patients. However, there exist many scenarios in which these markers fail to perform adequately. This is particularly true in the case of seminoma, where only 10% to 15% will have elevated serum tumor markers. Non-specific elevation of these markers is also a common occurrence, complicating the interpretation of borderline positive results, particularly in follow-up. To bridge this gap in performance, next generation biomarkers are being investigated. In this review, we consider the role of conventional serum tumor markers in GCT management and discuss recent advances in the next generation of biomarkers, with a focus on circulating microRNAs. We discuss the value that circulating microRNAs could bring as an addition to currently used markers, as well as potential weaknesses, in GCT management.

Sign in / Sign up

Export Citation Format

Share Document